In a sample of 400 phase II trials that included 25,000 participants, a total of 4,045 patients (16.2%) received a treatment ...
The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally ...
5h
Hosted on MSNFDA accepts BMS’ Opdivo-Yervoy combo sBLA for colorectal cancerThe US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence ...
Millions of American women are at high risk for breast cancer, but their insurance does not cover the costs of extra ...
Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its blockbuster cancer drug Keytruda in certain patients with head and neck cancer.
A jury found Naheed Mangi replaced patient medical data with erroneous information, insults about former boss.
Initial feasibility study of its soluble, Ph neutral, fast acting granular or powder drug delivery system is complete ...
A jury found Naheed Mangi replaced patient medical data with erroneous information, insults about former boss.
Threats of federal funding cuts are already felt within research circles at UNC, including the labs of some leading cancer ...
The FDA has granted priority review to the new drug application for zongertinib to treat adults with unresectable or metastatic, HER2-mutant NSCLC who have received prior systemic therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results